Nitrobenzamide Mustard Prodrugs Resistant to AKR1C3 Metabolism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nitroaromatic prodrugs, such as PR-104, are activated by human aldo-ketoreductase 1C3 (AKR1C3) in both aerobic and hypoxic conditions, leading to reduced selectivity for solid tumors over normal bone marrow, compromising their therapeutic index.
Innovation Solution
Development of nitrobenzamide mustards and their phosphate esters that are substantially resistant to AKR1C3 enzyme metabolism, allowing activation by nitroreductases or in hypoxic environments, thereby maintaining selectivity for tumor cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nitroaromatic prodrugs (such as PR-104) are used for cancer therapy, then tumor cell activation is achieved, but selectivity for solid tumors over normal bone marrow is reduced due to activation by human AKR1C3 enzyme in both aerobic and hypoxic conditions
Solution Approach 1:
The patent extracts the problematic AKR1C3 enzyme activation pathway from the prodrug system by designing nitrobenzamide mustards with structural modifications (specifically at the nitrogen atom position) that prevent binding to or activation by AKR1C3, while preserving activation by nitroreductases. This selective extraction of the harmful metabolic pathway achieves both tumor activation and normal tissue sparing.
Solution Approach 2:
The patent applies local quality by creating prodrugs with specific structural features (nitrobenzamide mustard core with modified nitrogen substituents) that confer different activation properties in different cellular environments. The compounds are designed to be activated specifically by nitroreductases in tumor cells while being resistant to AKR1C3 activation in normal bone marrow, achieving spatially selective activation.
2Productivity
If nitroaromatic prodrugs are administered to achieve cytotoxic effect, then tumor cells are killed, but side effects increase due to lack of selectivity
Solution Approach 1:
The patent removes the source of harmful side effects by eliminating AKR1C3 activation from the prodrug's metabolic pathways through structural modification. The nitrobenzamide mustard compounds are designed to bypass AKR1C3 metabolism entirely, channeling activation exclusively through nitroreductases that are overexpressed in tumor cells, thereby maintaining high cytotoxicity while eliminating bone marrow toxicity.
Solution Approach 2:
The patent converts the previously harmful non-selective activation by AKR1C3 into a beneficial selective activation mechanism. By designing prodrugs that are specifically activated by nitroreductases (which are beneficial enzymes in tumor cells) and made resistant to AKR1C3, the system transforms what was a source of toxicity into a source of selectivity, turning the tables on the metabolic activation process.
3Reliability
If conventional nitroaromatic prodrugs are used, then therapeutic activity is achieved, but solubility is poor leading to large variations in maximum tolerated dose
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical parameters of the prodrug molecules. The nitrobenzamide mustard compounds incorporate structural features that enhance aqueous solubility, allowing for consistent and reliable dosing. The modifications to the nitrogen atom substituents and overall molecular structure optimize both solubility and therapeutic activity, eliminating the dose variability problem associated with conventional prodrugs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate reduced metabolism by AKR1C3, enhancing selectivity for tumor cells and reducing side effects, with improved solubility and therapeutic efficacy, particularly in hypoxic tumor regions.
Implementation Method 1
Many nitroaromatic compounds can be reduced by both mammalian and bacterial flavoprotein enzymes, which effect stepwise addition of up to six electrons. The major enzymatic metabolite is usually the 4-electron reduced species (hydroxylamine).
Implementation Method 2
The 4-SO2Me derivative (compound 3, scheme 1) was also a substrate (Atwell et al., Anti-Cancer Drug Des., 1996, 11, 553), as was the dibromo mustard analogue (compound 4, scheme 1)
Implementation Method 3
Some phosphate analogues of mustards have been described, for the purpose of solubilising the compounds. The best known is estramustine phosphate
Implementation Method 4
In well-oxygenated tissues in the body the parent prodrug is re-formed in a futile redox cycle, however in the presence of pathological hypoxia found in human solid tumours, net reduction to hydroxylamine and amine cytotoxic metabolites is able to occur
Data Source
AI summary
The invention relates to compounds of use as targeted cytotoxic agents and methods of use thereof. In particular, the invention relates to prodrugs that are substantially resistant to human AKR1C3 enzyme metabolism, methods of cell ablation using said compounds and methods of treatment of cancer and other hyperproliferative disorders using said compounds.